Akebia Therapeutics Past Earnings Performance
Past criteria checks 0/6
Akebia Therapeutics has been growing earnings at an average annual rate of 17.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 5.4% per year.
Key information
17.5%
Earnings growth rate
31.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -5.4% |
| Return on equity | n/a |
| Net Margin | -26.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Akebia highlights late-stage vadadustat kidney disease study results
Apr 28Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?
Mar 31Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?
Mar 10Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?
Mar 10Revenue & Expenses BreakdownBeta
How Akebia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 195 | -52 | 100 | 63 |
| 30 Sep 23 | 194 | -59 | 105 | 0 |
| 30 Jun 23 | 201 | -98 | 114 | 0 |
| 31 Mar 23 | 271 | -56 | 120 | 0 |
| 31 Dec 22 | 292 | -94 | 139 | 130 |
| 30 Sep 22 | 294 | -158 | 153 | 0 |
| 30 Jun 22 | 294 | -163 | 168 | 0 |
| 31 Mar 22 | 221 | -276 | 177 | 0 |
| 31 Dec 21 | 212 | -282 | 174 | 0 |
| 30 Sep 21 | 211 | -299 | 170 | 0 |
| 30 Jun 21 | 222 | -300 | 163 | 0 |
| 31 Mar 21 | 259 | -392 | 157 | 0 |
| 31 Dec 20 | 295 | -385 | 154 | 0 |
| 30 Sep 20 | 308 | -391 | 159 | 0 |
| 30 Jun 20 | 340 | -386 | 153 | 0 |
| 31 Mar 20 | 351 | -268 | 153 | 0 |
| 31 Dec 19 | 335 | -280 | 149 | 0 |
| 30 Sep 19 | 325 | -245 | 137 | 0 |
| 30 Jun 19 | 286 | -217 | 113 | 0 |
| 31 Mar 19 | 234 | -193 | 89 | 0 |
| 31 Dec 18 | 208 | -144 | 87 | 0 |
| 30 Sep 18 | 238 | -68 | 40 | 0 |
| 30 Jun 18 | 227 | -65 | 36 | 0 |
| 31 Mar 18 | 206 | -53 | 30 | 0 |
| 31 Dec 17 | 181 | -74 | 27 | 0 |
| 30 Sep 17 | 92 | -127 | 26 | 0 |
| 30 Jun 17 | 51 | -140 | 24 | 0 |
| 31 Mar 17 | 22 | -154 | 22 | 0 |
| 31 Dec 16 | 2 | -136 | 22 | 0 |
| 30 Sep 16 | 0 | -118 | 22 | -29 |
| 30 Jun 16 | 0 | -101 | 21 | -13 |
| 31 Mar 16 | 0 | -76 | 20 | -7 |
| 31 Dec 15 | 0 | -61 | 18 | 0 |
| 30 Sep 15 | 0 | -51 | 18 | 34 |
| 30 Jun 15 | 0 | -41 | 17 | 25 |
| 31 Mar 15 | 0 | -38 | 15 | 24 |
| 31 Dec 14 | 0 | -124 | 15 | 0 |
| 30 Sep 14 | 0 | -123 | 12 | 22 |
| 30 Jun 14 | 0 | -120 | 10 | 18 |
| 31 Mar 14 | 0 | -164 | 8 | 15 |
| 31 Dec 13 | 0 | -69 | 7 | 9 |
Quality Earnings: AKBA is currently unprofitable.
Growing Profit Margin: AKBA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKBA is unprofitable, but has reduced losses over the past 5 years at a rate of 17.5% per year.
Accelerating Growth: Unable to compare AKBA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKBA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: AKBA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.